GlassScriptPhysician profile
James W Norcross
NPI 1851305809
$10,990.94
in general payments reported to CMS, 2019-2025
47 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,160 · 2020: $1,740 · 2021: $2,264 · 2022: $1,747 · 2023: $1,504 · 2024: $1,449 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,079.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,260.45 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,229.09 | 2019-2025 | |
| Gilead Sciences, INC. | $1,198.34 | 2019-2025 | |
| Lilly USA, LLC | $1,054.68 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Merck Sharp & Dohme LLC | $504.08 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $480.44 | 2019-2021 | |
| Pfizer INC. | $446.56 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $392.12 | 2019-2022 | |
| Glaxosmithkline, LLC. | $302.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Antares Pharma, INC. | $301.64 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Otsuka America Pharmaceutical, INC. | $298.49 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Optinose US, INC. | $261.32 | 2019-2025 | |
| Astellas Pharma US INC | $212.66 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $204.26 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.05 | 2019-2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $183.62 | 2020-2021 | |
| Eisai INC. | $176.59 | 2020-2022 | |
| Boston Scientific Corporation | $155.33 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Bausch Health US, LLC | $151.17 | 2019-2025 | Aplenzin |
| Biohaven Pharmaceuticals, INC. | $148.40 | 2021 | |
| Edwards Lifesciences Corporation | $140.93 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amarin Pharma, INC. | $137.85 | 2020-2021 | |
| Allergan, INC. | $132.96 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $121.61 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.58 | 2020-2021 | |
| Horizon Therapeutics Plc | $112.93 | 2019-2022 | |
| Viiv Healthcare Company | $110.66 | 2024-2025 | Apretude |
| Idorsia Pharmaceuticals US INC | $99.74 | 2022-2024 | Quviviq |
| Halozyme INC | $96.88 | 2023 | |
| Novo Nordisk INC | $92.12 | 2019-2022 | |
| Exact Sciences Corporation | $80.59 | 2023-2024 | Cologuard Collection Kit |
| Lundbeck LLC | $80.42 | 2023-2025 | Rexulti |
| Abbott Laboratories | $71.90 | 2022-2023 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $69.37 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $47.66 | 2023-2025 | Seglentis, Livalo, Zoryve |
| Sanofi Pasteur INC. | $46.23 | 2022-2023 | |
| Neuronetics, INC. | $39.87 | 2024-2025 | Neurostar Tms Therapy System |
| Aytu Biopharma, INC. | $37.11 | 2020 | |
| Dexcom, INC. | $33.59 | 2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $28.14 | 2023 | |
| Phathom Pharmaceuticals, INC. | $24.90 | 2024 | Voquezna |
| Azurity Pharmaceuticals, INC. | $23.39 | 2025 | Azmiro |
| Alexion Pharmaceuticals, INC. | $22.46 | 2021 | |
| Inspire Medical Systems, INC. | $21.55 | 2023 | Inspire |
| Lucid Diagnostics INC. | $16.89 | 2025 | |
| Tolmar, INC. | $13.18 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Norcross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.